This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Original paper

Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.

Volume: 36, Issue: 15_suppl, Pages: 5506 - 5506
Published: May 20, 2018
Abstract
5506 Background: Bevacizumab (BEV) is approved in recurrent ovarian cancer (rOC) for patients not previously treated with the drug. Our study aimed at evaluating whether the addition of BEV to a platinum-based chemotherapy prolongs progression-free survival (PFS) for rOC patients who had already received it during first line. Methods: FIGO stage IIIB-IV rOC patients relapsing at least 6 months after last dose of platinum, who had received BEV...
Paper Details
Title
Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.
Published Date
May 20, 2018
Volume
36
Issue
15_suppl
Pages
5506 - 5506
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.